{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-25-000115","form_type":"8-K/A","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.487211+00:00","generated_at":"2026-05-17T09:57:11.185986+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Salarius amends merger with Decoy; legacy holders diluted to 7.6%","bullets":["Effective ownership post-merger: Salarius legacy holders 7.6%, Decoy holders 92.4% (pre-Qualified Financing).","Salarius valuation reduced from $4.6M to $2.31M in Amendment 2; Decoy valued at $28M.","Qualified Financing requires minimum $6M; expected $8M from 1,470,588 shares at $5.44/share.","Amendment 4 removes threshold for anti-dilution adjustments; applies until Nasdaq listing & shareholder approval.","Merger accounted for as reverse asset acquisition with Decoy as accounting acquirer."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-25-000115","json":"https://secwatch.observer/filing/0001615219-25-000115.json","markdown":"https://secwatch.observer/filing/0001615219-25-000115.md","text":"https://secwatch.observer/filing/0001615219-25-000115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/0001615219-25-000115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521925000115/flks-20250822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:57:11.185986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}